
THE LONG ROAD TO TREATMENT

Medicare's CED Clinical Trial Policy Delays Patient Access

In an unprecedented decision, Medicare strictly limited coverage of new monoclonal antibody Alzheimer's therapies approved by FDA under Accelerated Approval for many living with mild Alzheimer's Disease. Under this new drug Coverage with Evidence Development (CED) policy, it could take up to **3 years** after a new drug is approved before patients have the opportunity to enroll in a qualifying CED clinical trial and receive treatment. At each step of the CED clinical trial process, there are multiple instances where patients could fail to receive the treatment they need.




3000 PEOPLE A DAY PROGRESS FROM MILD TO MODERATE ALZHEIMER'S

DISEASE.

trial: 18-24

-month process



Very few spots available

Screening

for clinical trial eligibility

- Limits on providers
- Limited locations/
 Poor to no rural access
 Dood and no treatment



Medicare beneficiaries shouldn't have to wait to recieve FDA-approved treatments. CED requirements are not the answer.

Learn more at pfcdalz.org.